
BPC-157
5mg · 10mg · 10mg · 10-Vial Kit
A synthetic pentadecapeptide studied in in-vitro models of tissue-repair signalling and cellular migration.
For research use only
RecoveryA thymosin beta-4 fragment investigated in research on cellular migration and angiogenesis pathways.
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino-acid peptide originally isolated from bovine thymus tissue. Its complete amino acid sequence was published in the Proceedings of the National Academy of Sciences in 1981, following work through the 1960s and 70s on biologically active thymus extracts — at that point it was understood as a thymic hormone and studied for its effect on thymocyte populations. The reframing came later, when Tβ4 was identified as a major G-actin sequestering protein. That reclassification, from immune factor to regulator of the cytoskeleton, is the reason the compound appears in tissue-repair literature at all.
Thymosin beta-4 is characterised as a principal G-actin sequestering peptide in mammalian cells: it binds monomeric (G-)actin and influences the balance between free monomer and polymerised filament, which governs cytoskeletal remodelling and cell migration. Later work has examined it as a target of hypoxia-inducible nitric oxide and HIF-1α regulation in cell-culture models. All of this is preclinical and in vitro. TB-500 is not FDA-approved for human use, and thymosin beta-4 is on the WADA Prohibited List.
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

5mg · 10mg · 10mg · 10-Vial Kit
A synthetic pentadecapeptide studied in in-vitro models of tissue-repair signalling and cellular migration.
For research use only

10mg · 20mg · 20mg · 10-Vial Kit
A combined preparation of BPC-157 and TB-500 used in comparative tissue-repair research models.
For research use only

70mg · 70mg · 10-Vial Kit
A combined BPC-157, GHK-Cu and TB-500 preparation studied in dermal and repair research contexts.
For research use only
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.